BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/22/2026 8:41:00 AM | Browse: 1 | Download: 0
 |
Received |
|
2026-01-22 02:04 |
|
Peer-Review Started |
|
2026-01-22 02:05 |
|
First Decision by Editorial Office Director |
|
2026-02-25 07:57 |
|
Return for Revision |
|
2026-02-25 07:57 |
|
Revised |
|
2026-03-10 15:37 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-04-20 02:54 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-20 08:11 |
|
Articles in Press |
|
2026-04-20 08:11 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-10 08:20 |
|
Publish the Manuscript Online |
|
2026-06-22 08:41 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the Editor: Reovirus as an immunomodulatory adjuvant in KRAS-mutant colorectal cancer - translational insights and future directions
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xin-Lei Zhou, Fan Chen and Kai-Bo Guo |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Natural Science Foundation of Zhejiang Province, China |
ZCLQ24H2901 |
| National Natural Science Foundation of China |
82405093 |
| Medical and Health Technology Program of Zhejiang Province, China |
2024KY1328 |
| Traditional Chinese Medicine Science and Technology Program of Zhejiang Province, China |
2024ZL712 |
|
| Corresponding Author |
Kai-Bo Guo, MD, Department of Oncology, Affiliated Hangzhou First People's Hospital , School of Medicine, Westlake University, No. 261 Huansha Road, Hangzhou 310006, Zhejiang Province, China. guokaibo@zcmu.edu.cn |
| Key Words |
Reovirus; KRAS mutation; Immune modulation; Tumor microenvironment; Metastatic colorectal cancer; Signaling pathway; Cytokine |
| Core Tip |
This study discussed that reovirus affects gene expression and cytokine secretion by regulating phosphatidylinositol 3-kinase/protein kinase B and other signaling pathways, thereby regulating the immune system and ultimately exerting an anti-KRAS mutant colon cancer effect. The letter proposes to more accurately elucidate the local immune regulation mechanism of reovirus through large-scale, multi-center randomized controlled trials, combined with tumor microenvironment analysis and combined immunotherapy design, and enrich experimental analysis methods, laying a good foundation for clinical application of reovirus. |
| Publish Date |
2026-06-22 08:41 |
| Citation |
Zhou XL, Chen F, Guo KB. Letter to the Editor: Reovirus as an immunomodulatory adjuvant in KRAS-mutant colorectal cancer - translational insights and future directions. World J Clin Oncol 2026; 17(6): 119152
|
| URL |
https://www.wjgnet.com/2218-4333/full/v17/i6/119152.htm |
| DOI |
https://doi.org/10.5306/wjco.119152 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
